{4-[(5-nitropyridin-2-yl)oxy]phenyl}methanol | 677303-05-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {4-[(5-nitropyridin-2-yl)oxy]phenyl}methanol
• 英文别名: [4-(5-nitropyridin-2-yl)oxyphenyl]methanol
• CAS: 677303-05-8
• 化学式: C₁₂H₁₀N₂O₄
• mdl: MFCD09754466
• 分子量: 246.222
• InChiKey: PCRWAOUYIABAAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  88.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {4-[(5-nitropyridin-2-yl)oxy]phenyl}methanol 在 铁粉 、 氯化铵 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 6-{4-[(3-fluorophenyl)methyl]phenoxy}pyridin-3-amine
  参考文献：
  名称：

  苯氧基吡啶衍生物作为钠钙交换剂的新型抑制剂的合成及其构效关系。

  摘要：

  钠钙交换剂（NCX）被称为控制心肌细胞中Ca（2+）浓度的转运蛋白。在心力衰竭和心肌缺血-再灌注的情况下，NCX是导致心律失常的瞬态内向电流的基础，该电流导致心动过速后的去极化和非折返性延迟。NCX是治疗心力衰竭和心肌缺血-再灌注的有吸引力的靶标。我们基于化合物3设计并合成了一系列苯氧基吡啶衍生物。已评估了这些衍生物对CCL39细胞中NCX反向和正向模式的抑制活性。我们发现了几种新型的有效NCX抑制剂（39q，48k），它们对反向NCX抑制活性具有很高的选择性。

  DOI：

  10.1016/j.bmc.2004.07.038
• 作为产物：
  描述：

  4-[(5-nitropyridin-2-yl)oxy]benzaldehyde 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 以71%的产率得到{4-[(5-nitropyridin-2-yl)oxy]phenyl}methanol
  参考文献：
  名称：

  苯氧基吡啶衍生物作为钠钙交换剂的新型抑制剂的合成及其构效关系。

  摘要：

  钠钙交换剂（NCX）被称为控制心肌细胞中Ca（2+）浓度的转运蛋白。在心力衰竭和心肌缺血-再灌注的情况下，NCX是导致心律失常的瞬态内向电流的基础，该电流导致心动过速后的去极化和非折返性延迟。NCX是治疗心力衰竭和心肌缺血-再灌注的有吸引力的靶标。我们基于化合物3设计并合成了一系列苯氧基吡啶衍生物。已评估了这些衍生物对CCL39细胞中NCX反向和正向模式的抑制活性。我们发现了几种新型的有效NCX抑制剂（39q，48k），它们对反向NCX抑制活性具有很高的选择性。

  DOI：

  10.1016/j.bmc.2004.07.038

文献信息

• Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient
  申请人：Takaoka Yoshikazu

  公开号：US20080057074A1

  公开（公告）日：2008-03-06

  A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  化合物由公式（I）所表示，其盐，其N-氧化物，其溶剂合物或其前药：（其中每个符号如描述中所定义）。 公式（I）所表示的化合物具有对CCR5的拮抗活性，因此它们在预防和/或治疗CCR5相关疾病方面非常有用，例如各种炎症性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿关节炎，鼻炎，结膜炎，溃疡性结肠炎等），免疫性疾病（自身免疫性疾病，器官移植排斥（固体器官移植排斥，治疗糖尿病的胰岛细胞移植排斥，移植物抗宿主病等），免疫抑制，牛皮癣，多发性硬化等），传染病（人类免疫缺陷病毒感染，获得性免疫缺陷综合征，RSV感染等），过敏性疾病（特应性皮炎，荨麻疹，过敏性支气管肺曲霉病，过敏性嗜酸性胃肠炎等），心血管疾病（动脉硬化，缺血再灌注损伤等），急性呼吸窘迫综合症，伴随细菌感染的休克，糖尿病，癌转移等。
• NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：TAKAOKA Yoshikazu

  公开号：US20110152520A1

  公开（公告）日：2011-06-23

  A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  化合物表示为公式(I)、其盐、N-氧化物、溶剂化合物或前药物：（其中每个符号如描述中所定义）。公式(I)所代表的化合物具有对CCR5的拮抗活性，因此它们在预防和/或治疗与CCR5相关的疾病方面非常有用，例如各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植排斥（固体器官移植排斥、治疗糖尿病的胰岛细胞移植排斥、移植物抗宿主病等）、免疫抑制、银屑病、多发性硬化等）、感染性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合症、RSV感染等）、过敏性疾病（特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性胃肠炎等）、心血管疾病（动脉硬化、缺血再灌注损伤等）、急性呼吸窘迫综合症、伴随细菌感染的休克、糖尿病、癌转移等。
• Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
  申请人：Ono Pharmaceutical Co., Ltd

  公开号：US08143404B2

  公开（公告）日：2012-03-27

  A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  化合物的化学式为(I)，其盐、N-氧化物、溶剂合物或前药：（其中每个符号如描述中所定义）。化学式(I)所代表的化合物具有对CCR5的拮抗活性，因此它们在预防和/或治疗CCR5相关疾病方面非常有用，例如各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植排斥反应（固体器官移植排斥反应、治疗糖尿病的胰岛细胞移植排斥反应、移植物抗宿主病等）、免疫抑制、银屑病、多发性硬化等）、感染性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合症、RSV感染等）、过敏性疾病（特应性皮炎、荨麻疹、变态反应性支气管肺曲霉病、过敏性嗜酸性胃肠炎等）、心血管疾病（动脉硬化、缺血再灌注损伤等）、急性呼吸窘迫综合症、细菌感染伴随的休克、糖尿病、癌症转移等方面也非常有用。
• Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US08604207B2

  公开（公告）日：2013-12-10

  A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  化合物的化学式为（I），其盐、N-氧化物、溶剂合物或前药：（其中每个符号的定义如说明书中所述。）化学式（I）所代表的化合物具有对CCR5的拮抗活性，因此它们在预防和/或治疗与CCR5相关的疾病方面非常有用，例如各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植排斥（固体器官移植排斥、治疗糖尿病的胰岛细胞移植排斥、移植物抗宿主病等）、免疫抑制、银屑病、多发性硬化等）、感染性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合症、RSV感染等）、过敏性疾病（特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性胃肠炎等）、心血管疾病（动脉硬化、缺血再灌注损伤等）、急性呼吸窘迫综合症、细菌感染性休克、糖尿病、癌转移等。
• Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2546234A1

  公开（公告）日：2013-01-16

  Compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof: (wherein the characters are as defined in the description). The compounds of the general formula (I) have a CCR5 antagonistic activity, so that they are useful in the prevention and/or therapy for CCR5 mediated diseases, for example, various inflammatory diseases (asthma, gastritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis and other inflammatory intestinal failure, etc.), immunologic diseases (autoimmune disease, rejection of transplanted organ (rejection of solid organ transplant graft, rejection of pancreatic islet cell transplant in diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (human immunodeficiency virus infection, acquired immunodeficiency syndrome, RSV infection, etc.) allergoses (atopic dermatitis, hives, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular risks (arteriosclerosis suppression of ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock caused by bacterial infection, diabetes, cancer metastasis, etc.

  通式 (I) 的化合物、其盐类和 N-氧化物，以及它们的溶解物和原药： (其中特征如描述中所定义）。通式（I）的化合物具有 CCR5 拮抗活性，因此可用于预防和/或治疗 CCR5 介导的疾病，例如各种炎症性疾病（哮喘、胃炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎和其他炎症性肠道衰竭等）、免疫性疾病（自身免疫性疾病）和其他疾病。免疫性疾病（自身免疫性疾病、移植器官排斥反应（实体器官移植移植物排斥反应、糖尿病患者胰岛细胞移植排斥反应、移植物抗宿主病等）、免疫抑制、银屑病等。心血管风险（动脉硬化抑制缺血再灌注损伤等）、急性呼吸窘迫综合征、细菌感染引起的休克、糖尿病、癌症转移等。